INTRODUCTION AND OBJECTIVES: Irreversible Electroporation (IRE) is an emerging ablative modality for patients with renal tumors that are not candidates for surgery or conventional thermal ablation. This study aims to evaluate technical success, safety, and outcomes for IRE treated complicated renal tumors.
METHODS: A single institution retrospective review of all renal tumors treated with Computed Tomography (CT) guided IRE between May 2013 and February 2016 was performed. A total of 17 patients underwent IRE with NanoKnife (AngioDynamics, Queensbury, New York) for primary or secondary renal malignancies. Technical success was defined as delivery of all planned pulses during ablation and verifying complete ablation by immediate post-procedure CT imaging. Local recurrence was defined as residual enhancement or increased tumor size following technical success. Follow-up imaging was scheduled at 1, 3, 6, 12, 18, and 24 months. Complications were defined using Clavien-Dino (CD) classification.
RESULTS: IRE was performed on 18 complicated renal tumors with median RENAL score of 6.5 ( 1st quartile 6, 3rd quartile 9) and median tumor size of 2.2 cm (1st quartile 2.0, 3rd quartile 3.1). Most were clear cell renal cell carcinomas (n¼13). Technical success was achieved in 17/18 tumor treatments (94.4%). One (5.6%) case was aborted due to bleeding (CD grade IIIb) requiring embolization. Minor CD grade one or two complications were present in 7/18 cases (38.9%), including post-procedural urinary retention (4/18, 22.2%), hypoglycemia (1/18, 5.6%), hematuria (1/18, 5.6%), and back pain (1/18, 5.6%). Patients lost to follow up were excluded (n¼3) from follow-up analysis. Median follow-up was 392 days, 1st quartile 203, 3rd quartile 696). Two local recurrences (14.2%) occurred on days 320 and 230 post-procedure with RENAL Scores of 9 and 8, respectively. Both cases were successfully treated with cryoablation and follow up showed no residual tumor at 723 and 617 days post cryoablation, respectively.
CONCLUSIONS: IRE appears to be a safe and efficacious option for the treatment of renal tumors in patients that are not candidates for surgery or thermal ablation techniques. Further research is warranted with larger sample sizes and continued follow up.
Source of Funding: none

MP100-14 HIGH INTENSITY FOCUSED ULTRASOUND KIDNEY ABLATION: PRE-CLINICAL SAFETY AND EFFICACY EVALUATION IN A PORCINE MODEL USING A 15MM LAPAROSCOPIC PROBE
Sameer Chopra*, Inderbir Gill, Alfredo Bove, Carlos Fay, Kevin King, Vinay Duddalwar, Toshitaka Shin, Rene Arboleda, Los Angeles, CA; Rodrigo Chaluisan, Jesse Clanton, Jacob Carr, Christie Johnson, Ben Ettinger, Adam Morris, Roy Carlson, Narendra Sanghvi, Mark Carol, Ralf Seip, Charlotte, NC INTRODUCTION AND OBJECTIVES: High intensity focused ultrasound (HIFU) has established itself clinically as a viable, safe, Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1335 effective, and non-invasive tissue ablation modality. Previous studies have shown that HIFU delivered laparoscopically can be used to ablate kidney tumors, potentially enabling a lower morbidity treatment with faster recovery time as compared to partial nephrectomy procedures. Challenges remain, however, including ensuring full tissue necrosis and consistent energy coupling to the target volume. The objective of this study was to evaluate whether a newly developed laparoscopic HIFU probe is able to address these challenges. METHODS: A laparoscopic porcine kidney model was used to investigate the safety and efficacy of the new 15mm HIFU probe. Under ultrasound guidance, kidneys of 12 pigs were targeted and ablated with HIFU, creating on average 2 ablation zones per kidney of varying sizes and locations in order to quantify the probe 0 s ability to deliver HIFU to any location on the kidney. Efficacy was evaluated via the analysis of ablation volume histology slides, real-time ultrasound images collected during HIFU delivery, and MRI and ultrasound contrast images. Safety was evaluated by surviving a subgroup of the animals (2w). Grosspathological data, sonication parameters, and workflow feedback was also collected during the study.
RESULTS: Repeatable lesions could be created at a rate of 0.48cm 3 /min and average energy densities of 584cal/cm 3 . Histological evaluation indicated contiguous ablated volumes using these delivery parameters, extending from the transducer 0 s focal zone to the kidney surface, with a maximum treatment depth of 27mm. Ablated target volumes ranged from 5.1cm 3 to 24.5cm 3 .
CONCLUSIONS: The results confirm the ability of the new probe to deliver HIFU in a consistent and reliable manner. Initial dose requirements for ablating tissue at various depths were also determined. Workflow feedback has resulted in additional system user interface improvements, with all of these results paving the way for a future clinical study.
Source of Funding: This work was supported by a Young
Investigator Award (S.C.).
MP100-15 LONG TERM ONCOLOGICAL OUTCOMES FOLLOWING RADIO FREQUENCY ABLATION OF RENAL MASS
Hariharan Ganapathi, Celebration, FL; Emily Fell Kelly, Boca Raton, FL; Aysswarya Manoharan, St Louis, MO; Manuel Molina, Miami, FL; Raymond J Leveillee*, Boynton Beach, FL INTRODUCTION AND OBJECTIVES: Widespread availability of cross sectional abdominal imaging increased the incidence of diagnosing low stage renal mass. Radio Frequency Ablation (RFA) is a treatment option in selected patients. Long-term outcome data is limited in the literature. We present our long-term follow up data after RFA METHODS: We reviewed the IRB approved RFA database at a tertiary care center. All patients were diagnosed with renal mass by contrast enhanced CT or MRI before surgery. They underwent laparoscopic RFA or computerized tomography guided RFA between November 2001 and August 2013. Patients were followed for tumor recurrence by contrast CT or MRI at 1 month, 6 months, 1 year and annually thereafter. Demographic and oncological follow up data were analyzed.
RESULTS: There were 398 patients underwent 466 RFA procedures for the median tumor size of 2.3cm. Their median age was 70 years (IQR 57-76), mean pre-operative creatinine was 1.13 (AE 0.41) and mean creatinine during most recent follow up visit was 1.18 (AE 0.49). Median follow up time was 48 months (IQR 46-150 months).
Radiographic failure (enhancement in the follow up CT/MRI) was diagnosed in 38 (9.5%) patients and 31 (82%) of them had follow up biopsy. Biopsy pathology showed renal cell cancer (RCC) in 18/31 (58%) patients (11 clear cell, 2 papillary and 5 unclassified RCC) and rest had normal renal parenchyma or non-diagnostic. Another thirteen patients developed new enhancing renal mass other than treated site during follow up. Total 36 patients (9%) required secondary treatment during follow up period (26 had repeat RFA, 7 had partial nephrectomy and 3 had radical nephrectomy). In total 33 (8.3%) patients deceased during follow up (3 due to metastatic RCC, one due to metastatic prostate cancer and others due to unrelated causes). Kaplan-Meier estimation of radiographic recurrence free survival was 90% at 5 years and 78% at 10 years. Five years cancer specific mortality was less than 1% and all-cause mortality was 8.3% following RFA.
CONCLUSIONS: RFA for renal mass has acceptable local recurrence rate (9.5%) diagnosed with regular follow up and can be effectively treated with secondary procedures. Cancer specific mortality is low (<1%) within median follow-up time of 48 months. This provides an alternate treatment option in selected patients. METHODS: We retrospectively analyzed 143 renal masses (128 patients) treated with LCA from 2001-2011, allowing for 5 year follow-up. Patients underwent retroperitoneal (RP) or transperitoneal (TP) LCA with objective thermal monitoring. After cryoneedle insertion, !2 thermal probes were placed within the tumor and outside the tumor margin to quantitatively assess temperatures. All tumors had !2 freeze cycles with a goal of achieving -25 C at the periphery. Core tumor biopsies (3-6) were taken under direct vision during the first freeze cycle. Follow-up was recommended at least annually. Patient characteristics, operative details, pathology and perioperative labwork were analyzed. All cases of post-ablative radiologic persistence (lesion at ablation site) and recurrence (lesion outside of ablation site) were confirmed with biopsy or pathology from additional surgery.
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